INTRODUCTION:

In medicine field, the tobramycin drug is a well known antibiotic drug. Tobramycin is an effective against bacteria and fungi. Tobramycin comes under aminoglycoside antibiotic. There is various another example of aminoglycoside Gentamycin, Tobramycin, Canamycin, Streptomycin etc. It is patented in 1965 and approved for medical use in 1974.Tobramycin is naturally antibiotic drug. It is obtain from streptomyces tenebrarius. Tobramycin ophthalmic will not treat for viral or fungal infection of the eye.

Tobramycin ophthalmic is used in treating only bacterial infection. Tobramycin does not cause the gastrointestinal tract so for systemic use it can be given by intravenous injection into a muscle. Tobramycin is anew aminoglycoside antibiotic with broad spectrum antibacterial activity. Tobramycin are most effective against pseudomonas aeruginosa, Serratia species, Enterobacter species, that is gram negative bacteria^1-2.

Antimicrobial Activity:

Tobramycin most affected gram negative bacteria. The tobramycin and gentamycin has similar activity. Tobramycin is most effective than gentamycin against pseudomonas aeruginosa.²

Chemical Structure:^3-4

Molar Mass: 467.515g/mol

Formula: C₁₈H₃₇N₅O₉

IUPAC Name: (2S,3R,4S,5S,6R)-4,6-diamino-3-{[2R,3R,5R,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-6-(hydroxy methyl)oxane-3,5-diol^1,2.

Figure 1: Structure of Tobramycin Drug

Doses Form of Tobramycin:

Tobramycin can be given in liquid form for intravenous and ointment form for Eye infection for inhalation it is present in solution and powder form ³.

Mechanism of Action of Tobramycin Drug:

Tobramycin penetrate bacterial cell membrane through aqueous pores and enters in periplasmic space- (Space between cell membrane and cytoplasmic membrane) this tobramycin transported across cell membrane to cytoplasm by oxygen dependent active transport so that disturb cell membrane and penetrate drug into bacterium from periplasmic space after enter into cytoplasm and binds to 30S ribosomal subunit and inhibit bacterial protein synthesis also blocks initiation of protein further more end of protein union. So that addition of incorrect amino acid hence synthesis of abnormal protein which may cause misreading amino acid which is not required for the synthesis of bacterial protein so that bacteria get death and gives bactericidal activity^5-6.

Pharmacokinetic Property:^7-8

Absorption:

Tobramycin manage by invert breath in cystic fibrosis patient showed a more noteworthy in consistency in sputum when contrasted with serum. After a solitary 112mg portion. The serum Cmax was 1.02 +/- 0.53 ug/ml, which was reached in 60min, while the sputum Cmax was 1048 +/- 1080ug/ml which was reached inside 60min, while the sputum Cmax was 737 +/- 1028 ug/gm. The foundational of openness was like comparative between the two doses at 4.6 +/- 2.0ug/ml for the 112 mg portion and 4.8 +/- 2.5ug.h/ml for the 300 mg portion. At the point when tobramycin was managed over a four week cycle at 112mg twice day by day, The Cmax estimated 1hr in the wake of dosing went from 1.48 +/- 0.69 ug/ml to 1.99 +/- 0.59ug/ml.

Distribution:

They are openly conveyed in the vascular space and the interstitial liquid of most tissues, because of their helpless restricting to proteins and their undeniable degree of dissolvability. They scarcely cross organic layers with the exception of the renal and internal ear cells, which show sufficient aminoglycoside take-up energy. One hour after organization, the pee focus is somewhere in the range of 25 and multiple times higher than plasmatic fixation and stays high for a few days. Vaporized organization accomplishes more prominent fixation in bronchial discharge than parenteral organization. They cross the blood-cerebrum obstruction inadequately, with the goal that when it is wanted to accomplish satisfactory focus in the cerebrospinal liquid, intraventricular or intrathecal organization⁵.

Metabolism:

Tobramycin isn’t apparently metabolized

Excretion:

All amino glycosides are discharged by glomerular filtration without past metabolic modification. Over 90% of the regulated portion is recuperated unaltered in the pee during the initial 24 hours; the rest can be identified in the pee for over 20 days. Gentamicin, tobramycin and netilmicin arrive at urinary fixations of 100 - 300μg/ml subsequent to overseeing intramuscular portions of 1 mg/kg and intravenous portion of 2 mg/kg, separately. After a portion of 7.5mg/kg amikacin intramuscularly or intravenously, the urinary fixation comes to up to 700-800μg/ml. The serum half-life of gentamicin, tobramycin, and netilmicin is 2 hours and amikacin somewhere in the range of 2 and 3 hours.with ordinary kidney work; nonetheless, those occasions are abbreviated if there should arise an occurrence of febrile sickness furthermore, drawn out with disintegration of kidney work⁵.

Protein Binding:

Tobramycin bind to serum protein is negligible and it has less than 30% protein binding with a volume of distribution of 30%, half life is near about 2hr, and dose in neonates 2mg/kg and in adult 3 to 4.5mg/kg.⁸

Pharmacodynamic:^9-10

AUC24/MIC proportion, Cm~ x (estimated or predicted 30 minutes after finish of imbuement), [Cmax]/VIIC proportion, Cmin, and t>MIC (calculated as a level of the dosing between val). Minimization of the least-squares misfortune work was utilized in the model. Logistic relapse with in reverse venturing was performed for additional testing of TBM- recognized breakpoints and for testing the probability of clinical fix in all patients above and underneath target AUC24/MIC proportions, Not withstanding treatment randomization. Nonlinear relapse examinations (SYSTAT form 9.0) with Hill-type capacities were used to infer models to describe the focus reaction relationship between the AUC24/MIC and t>MIC, continuous factors, and likelihood of clinical fix. Model separation was by Akaike's data measure. 16 Kruskal-Wallis nonparametric examination of fluctuation was utilized to test for contrasts in tolerant segment and pharmacokinetic single characteristics, and the Wilcoxon marked position test was utilized to decide the predisposition of the MAP-Bayesian calculations. Measurable importance for all examinations was set at P < 0.05. Like other aminoglycoside antibiotics, tobramycin is active in vitro in low concentrations against Staphylococcus aureus. Tobramycin is essentially inactive against Streptococcus pyogenes, Streptococcus [aecalis and Streptococcus pneumoniae (pneumoco~ci). Many studies have reported the relative activity of tobramycin and other aminoglycosides and of other antibiotics against various bacteria in vitro, but comparisons between studies cannot always be interpreted literally because the activity of many antibiotics in vitro, including tobramycin, is influenced by the nature of the culture media and the presence of certain salts. The sensitivity of P. aeruginosa to tobramycin is influenced by the magnesium, and calcium content of the culture media whilst that of all species is reduced by sodium ions. Wide variations in the concentration of these ions may result in divergent MIC values and an inappropriate choice of antibacterial alWnt to treat pseudomonas infection. In terms of the therapeutic ratio (LD, JED, o) tobramycin is the most active of the aminoglycosides in promoting survival in mice infected experimentally with P. aeruginosa. Tobramycin is more effective than gentamicin in suppressing experimental pseudomonas keratitis in rabbits. An increase in the bactericidal activity of tobramycin against some strains of P. aeruginosa is elicited by the addition of therapeutic concentrations of carbenicillin. However, as synergy could not be predicted from the susceptibility to the individual antibiotics, there is a need to perform appropriate laboratory studies for each strain. The activity of tobramycin in vivo against experimental infection is enhanced by the addition carbenicillin or cephalothin. Such studies provide the basis of controlled therapeutic trials with such antibiotic combinations, but to date such studies have not been reported. Some cross-resistance exists between tobramycin and gentamicin for P. aeruginosa, but is not complete. Pharmacokinetics: The pharmacokinetic properties of tobramycin in persons with normal renal function closely resemble those of gentamicin. In cross-over studies comparing gentamicin and tobramycin in healthy volunteers or in cancer patients with normal renal and hepatic function, peak serum levels after therapeutic doses given by the same route have been similar. Serum levels after intravenous administration are related to the dose and the rapidity of the injection or infusion. Low concentrations of tobramycin are present in CSF after parenteral administration and intrathecal or intraventricular administration is required to achieve therapeutic concentrations. An apparent volume of distribution equivalent to about 30% of the total body weight has been reported by some investigators whilst others have recorded lower values. The serum half-life of tobramycin in several studies has been about 2 hours. There seems to be some uncertainty regarding the degree to which tobramycin is bound to serum proteins. Whilst in one study a value of up to 70% was obtained with therapeutic concentrations, other workers consider that there is little or no serum binding. The latter view is probably correct. After intravenous or intramuscular injection tobramycin is rapidly excreted as the unchanged drug largely in the urine. It appears that the renal excretion of tobramycin, like that of gentamicin, is almost entirely by glomerular filtration. Renal clearance rates in different studies have varied from 76 to 92% of the total clearance. The urinary recovery has varied between 74 and 93% of a 100mg intravenous or intramuscular dose, most of which is recovered during the first 6 hours. The concentration of tobramycin in the urine is highest during the fust 2 to 3 hours after a dose and averages about 1501lg/ml after a 100mg dose. In patients with reduced renal function serum levels of tobramycin tend to be generally higher than in subjects with normal renal function given an equal dose. As the rate of elimination of tobramycin is related to creatinine clearance and to serum creatinine, the serum half-life is greatly increased in renal failure. Tobramycin is removed from the body relatively slowly by peritoneal dialysis, but is readily removed from the blood by haemodialysis.^10-13

Tobramycin Interaction:

Inform your primary care physician regarding every one of the drugs you take, including medicine and non-professionally prescribed medications, nutrients, and natural enhancements. Particularly tell your primary care physician in the event that you take: different anti-microbials like amoxicillin (Amoxil, Larotid, Moxatag, in Augmentin, in Prevpac), ampicillin, or penicillin dimenhydrate (Dramamine) meclizine (Bonine) nonsteroidal calming medications like indomethacin (Indocin, Tivorbex) This is certainly not a total rundown of tobramycin drug connections. Ask your primary care physician or drug specialist for more data¹⁴.

Uses:

Tobramycin is a physician recommended prescription used to treat contaminations of the eyes that care brought about by microbes.¹⁴

Inward Breath:

Tobramycin is a doctor prescribed drug used to treat diseases of the respiratory plot that care brought about by microbes in patients with cystic fibrosis.¹⁴

Injectable:

Tobramycin is a physician recommended medicine used to treat certain genuine contaminations that are brought about by microscopic organisms like meningitis (disease of the films that encompass the mind and spinal line) and diseases of the blood, mid-region (stomach region), lungs, skin, bones, joints, and urinary parcel¹⁵.

Adverse Effects:

Aminoglycosides are very well tolerated intravenously and intramuscularly and do not usually cause local inflammatory reaction. However, except for spectinomycin, all are potentially able to cause renal and optic toxicity, and rarely, neuromuscular block. Nephrotoxicity Considering an incidence ranging from 5% to 25%, nephrotoxicity is caused as consequence of the partial reabsorption of aminoglycosides by the epithelial cells of the proximal tubules. In most patients, nephrotoxicity is manifested through a non-oliguric renal failure. The tubular lesion is reversible and the renal function can be recovered in some patient despite of a continued administration of aminoglycosides. The risk of nephrotoxicity can be increased by an advanced age, hypovolemia, pre-existing nephropathy, liver disease, high doses, multidose administration, prolonged treatment, and simultaneous use of other nephrotoxic drugs. Serum aminoglycoside levels have been associated with nephrotoxicity; however, this affirmation has not been definitively established. Several substances have been investigated to reduce the nephrotoxicity of aminoglycosides; however, there are not conclusive statements regarding and this remains at a speculative level. On the other hand, single dose administration seems to be useful in reducing nephrotoxicity. Furthermore, nephrotoxicity appears more frequently if aminoglycosides are administered during the nocturnal rest hours, perhaps due to a lower alimentary: OtotoxicityAminoglycosides may cause Ototoxicity and sometimes it is irreversible. Auditory alterations are consequence of the destruction of outer hair cells in the organ of Corti, and vestibular lesions are due to destruction of hair cells located in both, the peripheral vestibular system and the central vestibular system. The central vestibular system is composed by parts of the brain and brainstem that process information obtained from the peripheral vestibular system regarding balance and spatial orientation At the initial stage of auditory toxicity, damage is limited to highest levels of frequency (4000 to 8000 Hz) and does not affect the frequencies used during a conversational hearing; toxic changes are generally reversible at this stage. If toxicity continues, the inner hair cells located at the cochlear apex will be affected, thus the lowest frequencies and conversational hearing are affected. At this stage the deficit is usually permanent or only partially reversible.The exact mechanism by which hair cells are destroyed in both forms of ototoxicity is unknown. Considering that the majority of patients are not followed after they are prescribed, and symptoms may be non-specific, it is unknown if ototoxicity is permanent or transient. However, treatments with a duration over 8 days, cumulative doses, high serum levels, treatment associated with diuretics, previous treatment with aminoglycosides and elderly have been associated with a higher incidence of ototoxicity. Recent studies have suggested that an accumulation of aminoglycosides in the cochlea and vestibule is more related to prolonged exposure than high transient serum levels. Neuromuscular blocker It very well may be brought about by a wide range of aminoglycosides and, albeit rare, is frequently serious and here and there lethal. It shows as shortcoming on respiratory musculature, limp loss of motion and mydriasis. It is related with illnesses or medications meddling with neuromuscular transmission and is identified with intravenous treatments; besides, hypomagnesemia, hypocalcemia and calcium channel blockers increment the danger. In expansion to steady measures, treatment requires the organization of intravenous^16-17.

Therapeutic trials: In limited therapeutic trials conducted mainly in North America, Europe and the United Kingdom tobramycin has been successfully used to treat infections in the urinary and respiratory tracts, septicaemia, meningitis and infections of the eye, ear, nose and throat and of skin and soft tissue caused principally by Gram-negative bacteria. Comparative trials to date have involved only small numbers of patients. Although the efficacy of tobramycin and gentamicin against infections caused by P. aeruginosa appears to be similar, further suitably designed trials in adequate numbers of patients are needed to determine the relative efficacy of tobramycin and gentamicin against serious infections caused by this species. Results obtained with tobramycin in urinary tract infections have generally been more impressive than those in infections of the lower respiratory tract or of skin and soft tissue. In children with lower respiratory tract infections associated with cystic fibrosis, best results were obtained with tobramycin 10mg/kg daily plus inhalation of 200rng daily. However, administration of a dose in the vicinity of 10mg/kg daily should not be undertaken unless the serum concentration of the drug can be monitored. Septicaemia caused by E. coli or Klebsiella spp. responded better to tobramycin at usual dosages than septicaemia caused by P. aeruginosa. There have been only a few cases of Gram-negative meningitis treated with tobramycin reported in the published literature. Results have been fair or poor when tobramycin has been given parenterally with or without concomitant intrathecal injection. It appears that optimum therapy in meningitis is likely to be associated with parenteral plus intraventricular injection particularly in moribund patients who have failed to respond to previous therapy with parenteral plus intrathecal aminoglycosides.^18-20

Side-Effects:

The most frequently reported adverse effects thought to be associated with the use of tobramycin have been a reduction in renal function, hearing disturbances and clinical evidence of ototoxicity and alterations in liver function test values. Dosage: The dosage of tobramycin is determined by the body weight of the patient and this must be obtained for calculation of correct dosage. The usual dose in adults and beyond the neonatal period is 1.0 to 1.5mg/kg 8-hourly (3 to 4.5mg/kg daily) in serious infections and 5 to 6mg/kg daily in life-threatening infections. Larger doses may be needed in some life-threatening infections. In neonates tne dosage is 2mg/kg 12-hourly (4mg/kg daily) intramuscularly or as a 2-hour intravenous infusion. In patients with impaired renal function serum levels of tobramycin should be monitored whenever possible. Following a loading dose of lmg/kg, subsequent dosage should be adjusted either by giving reduced doses at 8-houriy intervals or normal doses at increased intervals.^21-23

Apparent Volume of Distribution:

Although the apparent volume of distribution (A VD) of tobramycin has varied between studies the values for tobramycin and gentamicin have not been very different. An A YO of 22.4 litres for gentamicin and of 24.5 litres for tobramycin was reported. This is equivalent to about 30% of the total body weight. Values of 16.91itres and 14.5litres for tobramycin and gentamicin respectively were.^21-23

Animal Studies:

Concentrations of tobramycin and of gentamicin in the kidney tissue of rats after single subcutaneous injections reached levels of 50 to 60J.(g/gm compared with peak serum levels of 10J.(g/rnl. The serum half-life was 30 to 35 minutes but that in kidney tissue was 109 and 74 hours for gentamicin and tobramycin respectively. About 85% of the drug in kidney tissue was present in the cortex. In dogs given equal intravenous doses of gentamicin and tobramycin, Szwed et al. (1974) reported higher concentration of tobramycin in renal lymph and urine, but only within the nrst hour after administration. Concentrations in thoracic lymph and in serum were similar.^23-24

Half-Life:

As with other principal pharmacokinetic variables, the serum half-life of tobramycin is very similar to that of gentamicin. In most studies the serum half-life of tobramycin has been about 2 hours and that of gentamicin essentially the same.²⁵

Drug Repurposing of Tobramycin:

The absence of restorative alternatives to treat diseases brought about by multidrug-safe (MDR) microorganisms, particularly Gram-negative microscopic organisms, are evident. In this way, foster new procedures to resolve the issue of antimicrobial opposition. Repurposing non-anti-toxin business drugs for antimicrobial treatment presents a practical alternative. We evaluated six anticancer medications for their likely use in antimicrobial treatment. Here, we give in vitro proof that proposes possibility to repurpose the anticancer medication mitomycin C against MDR Gram-negative microbes. We additionally exhibited that mitomycin C, etoposide and doxorubicin were influenced by drug efflux in Pseudomonas aeruginosa. In blend with a tobramycin-ciprofloxacin anti-microbial half and half (TOB-CIP), the antibacterial movement of mitomycin C was improved against MDR clinical segregates of P. aeruginosa, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. Truth be told, 4 μg/mL (3 μM) TOB-CIP diminished the base inhibitory grouping of mitomycin C to ≤1 μg/mL against MDR Gram-negative microbes, with the exception of A. We showed that cooperative energy was innate to TOB-CIP and that neither tobramycin nor ciprofloxacin exclusively synergized with mitomycin C. Our discovering upholds recognizing adjuvant accomplices for mitomycin C, like TOB.CIP to Increase antimicrobial activity^26-28.

Incompatibility:

Tobramycin solutions are physically incompatible with heparin sodium. As with all aminoglycosides tobramycin is potentially incompatible chemically and/or physically with (Le. penicillins including carbenicillin, cephalosporins) depending on the pH and concentration of each antibiotic. Therefore, when multiple antibiotic therapy is necessary each drug should be administered separately^29-30.

CONCLUSION:

Tobramycin is a powerful and effective aminoglycoside approved for complicated infection with various indication because of having a weak binding affinity to the rRNA of prokaryotes, it can cause serious adverse events in patient. The primary bacterial intracellular site of tobramycin action is the 30s ribosome subunit

REFERENCE:

1. Abbas HA, Serry FM, El-Masry EM. Non-steroidal anti-inflammatory drugs and sodium ascorbate potentiate the antibiotic activity against Pseudomonas aeruginosa biofilms. Research Journal of Pharmacy and Technology. 2012; 5(8):1124-9.

2. Malviya V. Preparation and Evaluation of Emulsomes as a Drug Delivery System for Bifonazole. Indian Journal of Pharmaceutical Education and Research. 2021 Jan 1;55(1):86-94.

3. Abbas HA, Serry FM, EL-Masry EM. N-acetylcysteine and Ambroxol: can mucolytics dissolve the resistance of biofilms to antibiotics. Research Journal of Pharmacy and Technology. 2012;5(7):912-7.

4. Malviya VR, Pande SD, Bobade NN. Preparation and Evaluation of Sustained Release Beads of Zolmitriptan Hydrochloride. Research Journal of Pharmacy and Technology. 2019;12(12):5972-6.

5. Abbas HA, Serry FM, EL-Masry EM. Biofilms: The microbial castle of resistance. Research Journal of Pharmacy and Technology. 2013;6(1):1-3.

6. Abbas HA, El-Saysed MA, Ganiny AM, Fattah AA. Antimicrobial Resistance Patterns of Proteus mirabilis isolates from Urinary tract, burn wound and Diabetic foot Infections. Research Journal of Pharmacy and Technology. 2018;11(1):249-52.

7. Al-Faqeeh LA, Naser R, Kagne SR. Determination of antibiotic resistant profiles for bacteria isolated from clinical samples in Aurangabad, India. Research Journal of Pharmacy and Technology. 2020;13(8):3813-6.

8. Al-Oqaili NA, Al-Shebli MK, Almousawi AN. Molecular Characterizations of Aminoglycoside Modifying Enzymes of Proteus mirabilis Isolated From Patients in Al-Qadisiyah Governorate. Research Journal of Pharmacy and Technology. 2018;11(7):2809-13.

9. Malviya V, Thakur Y, Gudadhe SS, Tawar M. Formulation and evaluation of natural gum based fast dissolving tablet of Meclizine hydrochloride by using 3 factorial design 2. Asian Journal of Pharmacy and Pharmacology. 2020;6(2):94-100.

10. Rana S, Sirwar SB. Prevalence and Antibiogram of Extended Spectrum β-Lactamase Producing Klebsiella pneumoniae and Proteus mirabilis in UTI. Research Journal of Pharmacy and Technology. 2015;8(11):1465-8.

11. Malviya V, Ladhake V, Gajbiye K, Satao J, Tawar M. Design and Characterization of Phase Transition System of Zolmitriptan Hydrochloride for Nasal Drug Delivery System. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020 May 31;13(3):4942-51.

12. Malviya VR, Tawar MG. Preparation and Evaluation of Oral Dispersible Strips of Teneligliptin Hydrobromide for Treatment of Diabetes Mellitus. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020 Jan 31;13(1):4745-52.

13. Rao US, Khamsah SM, Atif AB, Latif AZ. Scopoletin (Coumarin extracted from Mengkudu): Chemical, Biological, Molecular and Pharmacokinetic insights–A Review. Research Journal of Pharmacy and Technology. 2013;6(9):978-84.

14. Malviya V, Manekar S. Design, Development and Evaluation of Aceclofenac and Curcumin Agglomerates by Crystallo Co-Agglomeration Technique. Research Journal of Pharmacy and Technology. 2021 Mar 18;14(3):1535-41.

15. Malviya VR, Pande SD. Road CKN. Preparation ad Evaluation of Zolmitriptan Hydrochloride Lozenge. J Pharma Res. 2019;8(8):624-9.

16. Neu HC. Tobramycin: an overview. The Journal of infectious diseases. 1976 Aug 1:S3-19.

17. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. New England Journal of Medicine. 1999 Jan 7;340(1):23-30.

18. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, Wentz K. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. New England Journal of Medicine. 1993 Jun 17;328(24):1740-6.

19. Nichols WW, Dorrington SM, Slack MP, Walmsley HL. Inhibition of tobramycin diffusion by binding to alginate. Antimicrobial agents and chemotherapy. 1988 Apr;32(4):518-23.

20. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI®). Drugs. 2003 Nov;63(22):2501-20.

21. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002 Jul 1;122(1):219-26.

22. Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Alimentary pharmacology & therapeutics. 1990 Apr;4(2):123-9.

23. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002 Jul 1;122(1):219-26.

24. Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrobial agents and chemotherapy. 1985 Apr;27(4):619-24.

25. Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrobial agents and chemotherapy. 1985 Apr;27(4):619-24.

26. Domalaon R, Ammeter D, Brizuela M, Gorityala BK, Zhanel GG, Schweizer F. Repurposed antimicrobial combination therapy: Tobramycin-ciprofloxacin hybrid augments activity of the anticancer drug mitomycin C against multidrug-resistant Gram-negative bacteria. Frontiers in microbiology. 2019 Jul 10;10:1556.

27. Rampogu S, Lee KW. Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics. Frontiers in Chemistry. 2021;9.

28. Maiden MM, Zachos MP, Waters CM. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential. Journal of Antimicrobial Chemotherapy. 2019 Apr 1;74(4):894-906.

29. Ahmed MZ, Zia Q, Haque A, Alqahtani AS, Almarfadi OM, Banawas S, Alqahtani MS, Ameta KL, Haque S. FDA-approved antiviral and anti-infection agents as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study. Journal of Infection and Public Health. 2021 Feb 9.

30. Burange PJ, Tawar MG, Bairagi RA, Malviya VR, Sahu VK, Shewatkar SN, Sawarkar RA, Mamurkar RR. Synthesis of silver nanoparticles by using Aloe vera and Thuja orientalis leaves extract and their biological activity: a comprehensive review. Bulletin of the National Research Centre. 2021 Dec;45(1):1-3.

Received on 30.08.2021 Modified on 01.01.2022

Asian J. Res. Pharm. Sci. 2022; 12(2):137-142.

DOI: 10.52711/2231-5659.2022.00023